“These are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential,” says the author of today’s article of the five stocks he highlights, all of which are smaller-cap tech companies trading under the $10 level. For these five tech stocks, CLICK HERE.
A rumored takeover candidate is among the five small-cap biotech stocks trading under $10 highlighted in today’s article, all of which boast Buy ratings from well-known Wall Street firms – and solid upside potential. For these five biotech stocks, which are suited for very aggressive investors, CLICK HERE.
While the best way to ride the marijuana legalization wave may be through exchange-traded funds, for those interested in specific stock ideas, which marijuana stocks are analysts’ favorites? Today’s article sifts through the holdings of the six largest marijuana ETFs to identify them. For a list of these marijuana stocks and their respective upside potential, CLICK HERE.
“We stick to our view that 2021 will be a stockpicker’s paradise with big money-making opportunities if you are willing to go against the grain,” asserts one small/mid-cap stock strategist cited in today’s article, which proceeds to highlight two penny stocks that boast “Strong Buy” consensus ratings and upside potential over 200%. For these two penny stocks, CLICK HERE.
“These are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential,” declares the author of today’s article of the five Buy-rated stocks trading under $10 that he highlights. Among them are a late-stage pharmaceutical company focused on developing potential new therapies for cancer, a security technology company that provides email encryption…
With the global market for head and neck cancer expected to reach $4.5 billion by 2027, the clinical-stage immuno-oncology company highlighted in today’s article – which has entered into a clinical trial collaboration with Merck to treat patients with head and neck squamous cell carcinoma with its lead product candidate – has massive upside potential. For more on this company…
When it comes to the uncertainty that currently permeates the market as a result of the pandemic and impending election, the chief investment strategist at Oppenheimer is choosing to embrace it. As a result, today’s article takes a look at two specific stocks Oppenheimer is bullish on – and which its analysts believe have over 100% upside potential (792% in…
“As an investor, this sets up a great opportunity to get in on the ground floor and earn triple-digit profits in short order,” advises the author of today’s article in regards to a little-known segment of the thriving biotech industry that appears poised for a massive breakout to the upside in the coming months. Just what is this biotech segment…
Clinical trial data or regulatory verdicts can send shares of biotech companies skyrocketing – or plummeting. The question then, as the author of today’s article observes, is “how are investors supposed to determine which biotech stocks are capable of outperforming the rest?” One approach is to track analyst sentiment – and the author highlights three biotech stocks that not only…
Today’s article highlights two “compelling small-cap stocks that combine a low cost of entry with the Street’s backing.” More specifically, these two stocks – a biotech firm and a pharmaceutical company – are currently trading for less than $8 a share, have earned “Strong Buy” consensus analyst ratings, and boast significant upside potential. For more, CLICK HERE.